A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

Elevance became the fourth major health insurer to lower or scrap its profit forecast, with the CFO call citing a ...

Getting Coca-Cola to use cane sugar rather and ice cream manufacturers to stop their use of synthetic dyes are the latest ...

The people most at risk from suicide aren’t adolescents in angst or those experiencing a midlife lull, but men age 75 and ...

Over the last nine months, four senators led by Sen. Dick Durbin (D-Ill.) have conducted an inquiry into the growing ...

Medicare wants to allow far more more surgeries to be done in outpatient facilities like ambulatory surgery centers.

In a new study, Nobel laureate David Baker and colleagues detail new methods for targeting undruggable "disordered" proteins.

Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...

In today's Morning Rounds newsletter: the end of 988’s LGBTQ+ line, everything you need to know about the HHS deputy nominee, ...

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...

The FDA is allowing Juul to keep its e-cigarettes on the market, providing relief to a company that has struggled for years ...